1. Home
  2. HWH vs LNAI Comparison

HWH vs LNAI Comparison

Compare HWH & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HWH International Inc.

HWH

HWH International Inc.

HOLD

Current Price

$1.44

Market Cap

11.0M

Sector

Health Care

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

HOLD

Current Price

$2.15

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWH
LNAI
Founded
2021
N/A
Country
United States
United States
Employees
N/A
29
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.0M
12.4M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
HWH
LNAI
Price
$1.44
$2.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.5K
34.8K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
47.37
N/A
EPS
N/A
N/A
Revenue
$866,926.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.15
52 Week High
$7.77
$5.02

Technical Indicators

Market Signals
Indicator
HWH
LNAI
Relative Strength Index (RSI) 55.52 37.61
Support Level $1.38 $0.85
Resistance Level $1.45 $3.09
Average True Range (ATR) 0.07 0.20
MACD 0.02 -0.11
Stochastic Oscillator 70.59 4.19

Price Performance

Historical Comparison
HWH
LNAI

About HWH HWH International Inc.

HWH International Inc and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore. The Company is presently developing Hapi Marketplace, a business-to-consumer platform featuring diverse product categories, and Hapi Wealth Builder, an educational program focused on wealth-building strategies.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: